Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.
Assessment of system dysfunction in the brain through MRI-based connectomics.
A novel method for calculating prevalence of multiple sclerosis in Australia.
Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?
The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.
The primary vascular dysregulation syndrome: implications for eye diseases.
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01)
Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis.
Update on multiple sclerosis treatments.
Management of faecal incontinence and constipation in adults with central neurological diseases.
Discovery of A-971432, an Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonists for the Potential Treatment of Neurodegenerative Disorders.
Resistance training and vibration improve muscle strength and functional capacity in female patients with multiple sclerosis.
Effects of Physical Exercise on Neuroinflammation, Neuroplasticity, Neurodegeneration, and Behavior: What We Can Learn From Animal Models in Clinical Settings.
VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
Anti-AQP(4) antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis.
Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.
Expression Analysis of CB2-GFP BAC Transgenic Mice.
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report.
Complex assessment in progressive multiple sclerosis: a case report.
Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention.
Protective Role of (RS )-glucoraphanin Bioactivated with Myrosinase in an Experimental Model of Multiple Sclerosis.
Multiple sclerosis: Clinical characteristics and disability progression in Moroccan children.

Pages